Established in June 2022, Coalescence BioPharma, LLC is a U.S.-based biotech advisory and strategic collaboration platform focused on innovative biopharmaceutical programs and international business development. We support scientific evaluation, asset positioning, licensing activities, and cross-border partnership initiatives involving clinical-stage and commercial-stage therapeutic opportunities. Through collaborations with innovators, pharmaceutical companies, and investors, we help facilitate strategic opportunities across China, North America, Europe, and Japan.
Our Management Team
Dr. Jianwen Zhang
Founder & Former CEO | Scientific & Strategic Advisor
Dr. Jianwen Zhang brings over 30 years of experience spanning drug discovery, translational research, and international biopharmaceutical business development.His career includes leadership roles in both biotechnology and pharmaceutical organizations, with contributions to programs in rare diseases, antiviral therapies, oncology, immunology, and innovative biologics. He has extensive experience in scientific evaluation, strategic positioning, licensing activities, and global partnering initiatives.Dr. Zhang currently supports international business development and strategic collaboration activities through Angine Biotech and an expanding global network of pharmaceutical and biotechnology partners.Recent activities include participation in cross-border licensing collaborations involving Bijuva® (Women's Health) and Inbrija® (Parkinson's Disease) for the Greater China market, as well as global partnering initiatives for innovative clinical-stage therapeutic programs.
Zhiping Weng, MS
Managing Director, Strategic Operations
Ms. Zhiping Weng brings extensive experience in scientific research, bioinformatics, and international project coordination.Her academic and professional background spans China, Europe, and the United States, supporting cross-border scientific communication and strategic collaboration initiatives.At Coalescence BioPharma, she supports strategic operations, international partnership activities, and coordination of innovative biopharmaceutical programs.
